The altered expression of HANR affects the sensitivity of HCC to doxorubicin by suppressing glycogen synthase kinase-3 beta (GSK3β) phosphorylation and upregulating GSK3β total protein expression. This evidence concerns the gene GSK3B and hepatocellular carcinoma.